Ani Pharmaceuticals Inc. (anip 2.25 09/01/29)
13F holders, Q4 2025 (December 31)4holders +1
1new positions
0sold out
$2.70avg. 13F price*
At the end of Q4 2025, 4 institutions reported holding Ani Pharmaceuticals Inc. (anip 2.25 09/01/29) in their 13F filings, up 1 from Q3 2025. 1 opened new positions and 0 sold out. The largest holders were Boussard & Gavaudan Investment Management LLP ($23.6M), Absolute Investment Advisers, LLC ($14.5M) and Picton Mahoney Asset Management ($5.0M).
- Company
- Ani Pharmaceuticals Inc. (anip 2.25 09/01/29)
- CUSIP
- 00182CAC7
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $5.0M |
| Exits | 0 | $0 |
All 13F filers, Q3 2025 → Q4 2025: 4,158,500 shares bought, net +4,158,500 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Boussard & Gavaudan Investment Management LLP | 3.57% | Add +85.0% | 18,500 | $23.6M |
| Absolute Investment Advisers, LLC | 1.65% | No change | 11,473,000 | $14.5M |
| Picton Mahoney Asset Management | 0.06% | New | 4,000,000 | $5.0M |
| Bank of New York Mellon Corp | 0.00% | Add +21.4% | 850,000 | $1.1M |
"% of holder's portfolio" is ANI PHARMACEUTICALS INC (ANIP 2.25 09/01/29)'s weight in each manager's 13F, not the share of Ani Pharmaceuticals Inc. (anip 2.25 09/01/29) the manager owns.